We’ve recently reached out to the leaders in the field of orphan drugs and rare diseases, in order to ask some fundamental questions on the current state of the industry and how it stands to progress from now until 2025.
The Future of the Orphan Drug Industry outlines some of the leading viewpoints from the likes of high-level executives and/or key decision makers from SCAD, AKU Society, Pfizer, Oxford PharmaGenesis and INSERM, just to name a few. Those who have offered their opinion will be speaking in further detail at the World Orphan Drug Congress, 12-14 November 2014.
A selection of the questions asked are:
- What are some of the biggest challenges you are currently facing and how does your talk try to address this?
- How do you think the role of patients/patient advocates/patient groups will change?
- What do you think will be the single biggest trend or change to the orphan and rare disease sector between now and 2025?
- Why are patient and academic collaborations developing rare disease diagnostics and therapies at the top of your agenda right now?
- What alternative funding sources for orphan drug development will be discussed in your talk?
- What are your predictions for the future use of social media and digital networks in the orphan sector?
- How do you think changes to licencing and approval processes (i.e. fast track and adaptive licencing) will impact on the sector as a whole?
Download this eBook now.
To hear more about the developments within orphan and rare diseases, come along to the Congress and become a part of the conversations that’ll shape the foreseeable future of the industry.
Image from Flickr